KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Long-Term Deferred Tax: 2009-2025

Historic Long-Term Deferred Tax for Halozyme Therapeutics (HALO) over the last 1 years, with Jun 2025 value amounting to $20.2 million.

  • Halozyme Therapeutics' Long-Term Deferred Tax was N/A to $20.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $3.9 million for FY2024, which is 12.11% down from last year.
  • Halozyme Therapeutics' Long-Term Deferred Tax amounted to $20.2 million in Q2 2025, which was up 289.36% from $5.2 million recorded in Q1 2025.
  • In the past 5 years, Halozyme Therapeutics' Long-Term Deferred Tax registered a high of $155.4 million during Q4 2021, and its lowest value of $616,000 during Q1 2024.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $9.3 million (2023), whereas its average is $13.4 million.
  • In the last 5 years, Halozyme Therapeutics' Long-Term Deferred Tax crashed by 98.27% in 2024 and then skyrocketed by 742.53% in 2025.
  • Halozyme Therapeutics' Long-Term Deferred Tax (Quarterly) stood at $155.4 million in 2021, then slumped by 71.42% to $44.4 million in 2022, then crashed by 90.13% to $4.4 million in 2023, then dropped by 12.11% to $3.9 million in 2024, then surged by 742.53% to $20.2 million in 2025.
  • Its Long-Term Deferred Tax was $20.2 million in Q2 2025, compared to $5.2 million in Q1 2025 and $3.9 million in Q4 2024.